Macrocycles in Drug Discovery
This book reviews macrocycles in drug discovery, both those of natural origin and semi-synthetic derivatives of natural products, and those designed and synthesized based on principles of medicinal chemistry.
The medicinal chemistry of macrocyclic natural products is interesting in itself, but lessons learned from these compounds, in terms of the relationship between structure and desirable physicochemical properties, are now informing the design of fully synthetic macrocyclic drug candidates against a variety of targets including kinases, ATPases, proteases, GPCRs and others. Furthermore, as more non-classical drug targets, such as protein–protein interactions, are pursued in the pharmaceutical industry, macrocyclic molecules are generating increasing interest as they offer a way to provide drug–protein interactions that cover a larger surface area than traditional small molecules.
A variety of macrocycles have become important drugs or have been identified as leads to marketed drugs. This text will discuss these compounds, their pharmacology and synthesis, in the context of their broad chemotype as compounds composed of large rings. Providing a wide reaching review of this important area in a single volume, this book will be of interest to biochemists, pharmaceutical scientists and medicinal chemists working in industry or academia.
Macrocycles in Drug Discovery, The Royal Society of Chemistry, 2014.
Download citation file:
Digital access
Print format
Table of contents
-
CHAPTER 1: Bioactive Macrocycles from Nature1p1-36ByDavid J. Newman;David J. NewmanNatural Products Branch, Developmental Therapeutics Program, DCTD, NCIFrederick National LaboratoryP. O. Box BFrederickMD 21702USA[email protected]Search for other works by this author on:Gordon M. CraggGordon M. CraggNatural Products Branch, Developmental Therapeutics Program, DCTD, NCIFrederick National LaboratoryP. O. Box BFrederickMD 21702USA[email protected]Search for other works by this author on:
-
CHAPTER 2: Recent Advances in Macrocyclic Hsp90 Inhibitorsp37-77ByR. R. A. Kitson;R. R. A. KitsonSchool of Chemistry, University of NottinghamUniversity ParkNottinghamNG7 2RDUKSearch for other works by this author on:C. J. Moody;C. J. MoodySchool of Chemistry, University of NottinghamUniversity ParkNottinghamNG7 2RDUKSearch for other works by this author on:S. R. McAlpineS. R. McAlpineSearch for other works by this author on:
-
CHAPTER 3: Epothilonesp78-108ByRaphael Schiess;Raphael SchiessDepartment of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology (ETH) ZürichHCI H405, Vladimir-Prelog-Weg 4CH-8093ZürichSwitzerland[email protected]Search for other works by this author on:Karl-Heinz AltmannKarl-Heinz AltmannDepartment of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology (ETH) ZürichHCI H405, Vladimir-Prelog-Weg 4CH-8093ZürichSwitzerland[email protected]Search for other works by this author on:
-
CHAPTER 4: Macrocyclic Inhibitors of Zinc-dependent Histone Deacetylases (HDACs)p109-140ByA. GanesanA. GanesanSchool of Pharmacy, University of East AngliaNorwich Research ParkNorwich NR4 7TJUK[email protected]Search for other works by this author on:
-
CHAPTER 5: Designed Macrocyclic Kinase Inhibitorsp141-205ByAnders Poulsen;Anders PoulsenExperimental Therapeutics Centre, A*STAR11 Biopolis Way, #03-10/11 The Helios138667SingaporeSearch for other works by this author on:Anthony D. William;Anthony D. WilliamInstitute of Chemical and Engineering Sciences, A*STAR11 Biopolis Way, The Helios #03-08138667SingaporeSearch for other works by this author on:Brian W. DymockBrian W. DymockDepartment of Pharmacy, National University of Singapore18 Science Drive 4117543Singapore[email protected]Search for other works by this author on:
-
CHAPTER 6: Anti-Inflammatory Macrolides to Manage Chronic Neutrophilic Inflammationp206-234ByMichael Burnet;Michael BurnetSynovo GmbH, TübingenGermanySearch for other works by this author on:Jan-Hinrich Guse;Jan-Hinrich GuseSynovo GmbH, TübingenGermanySearch for other works by this author on:Hans-Jürgen Gutke;Hans-Jürgen GutkeSynovo GmbH, TübingenGermanySearch for other works by this author on:Loic Guillot;Loic GuillotINSERM, UMR_S 938CDR Saint-AntoineParisFranceSearch for other works by this author on:Stefan Laufer;Stefan LauferThe University of TübingenGermanySearch for other works by this author on:Michael P. Seed;Michael P. SeedUniversity of East LondonLondonUKSearch for other works by this author on:Enriqueta Vallejo;Enriqueta VallejoSynovo GmbH, TübingenGermanySearch for other works by this author on:Doug McKenzie;Doug McKenzieStressor Therapeutics Ltd, 10782 Spur PointSan DiegoCA 92130USASearch for other works by this author on:Wolfgang Albrecht;Wolfgang Albrechtc-a-i-r biosciences GmbH, TübingenGermanySearch for other works by this author on:Michael J. ParnhamMichael J. ParnhamFraunhofer Institute for Molecular Biology and Applied Ecology IME-TMPFrankfurt am MainGermany[email protected]Search for other works by this author on:
-
CHAPTER 7: Linear and Macrocyclic Hepatitis C Virus Protease Inhibitors: Inhibitor Design and Macrocyclization Strategies for HCV Protease and Related Targetsp235-282ByJacob J. Plattner;Jacob J. PlattnerAnacor Pharmaceuticals, Inc., 1020 E. Meadow CirclePalo AltoCA 94303USASearch for other works by this author on:Xianfeng LiXianfeng LiAnacor Pharmaceuticals, Inc., 1020 E. Meadow CirclePalo AltoCA 94303USASearch for other works by this author on:
-
CHAPTER 8: Macrocyclic Inhibitors of GPCR's, Integrins and Protein–Protein Interactions1p283-338ByPhilipp Ermert;Philipp ErmertPolyphor LtdHegenheimermattweg 125CH-4123AllschwilSwitzerlandSearch for other works by this author on:Daniel ObrechtDaniel ObrechtPolyphor LtdHegenheimermattweg 125CH-4123AllschwilSwitzerlandSearch for other works by this author on:
-
CHAPTER 9: Macrocyclic α-Helical Peptide Drug Discoveryp339-366ByEric FeyfantEric FeyfantSearch for other works by this author on:
-
CHAPTER 10: Optimizing the Permeability and Oral Bioavailability of Macrocyclesp367-397BySiegfried S. F. Leung;Siegfried S. F. LeungCircle Pharma, Inc.San FranciscoCA 94107Search for other works by this author on:Matthew P. JacobsonMatthew P. JacobsonDepartment of Pharmaceutical Chemistry, University of California San FranciscoSan FranciscoCA 94158USASearch for other works by this author on:
-
CHAPTER 11: The Synthesis of Macrocycles for Drug Discoveryp398-486ByMark L. PetersonMark L. PetersonSearch for other works by this author on:
Spotlight
Advertisement
Advertisement